Translating AAD/NPF Guidelines to Lower Cardiovascular Risk in Patients with Psoriasis

The discussion focused on translating AAD (American Academy of Dermatology) and NPF (National Psoriasis Foundation) guidelines to lower cardiovascular risks in psoriasis patients. The speaker highlighted an NIH grant proposal to study tirzepatide's effectiveness for managing psoriasis among overweight patients, emphasizing the intersection of skin disease and cardiovascular health. They pointed out the bidirectional relationship between psoriasis and cardiovascular disease, where worsening psoriasis may indicate underlying cardiovascular issues, and vice versa. Data from various studies were presented, showing that psoriasis severity correlates with increased cardiovascular risks and mortality, and that patients often go untreated for cardiovascular factors. The talk underscored the importance of educating patients about their cardiovascular risks, alongside consistent screening for hypertension, diabetes, and cholesterol levels, particularly for moderate to severe psoriasis cases. The speaker stressed the need for dermatologists to recognize these risk factors, engage with cardiologists, and implement the guidelines effectively to shift practice. The presentation also detailed the challenges in definitively proving the cardiovascular benefits of psoriasis treatments and the ongoing research required. Ultimately, the take-home message was to encourage dermatologists to educate, screen, and advocate for aggressive treatment of comorbid cardiovascular risks in their psoriasis patients, leveraging the trust built through successful skin treatment.